DKA

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Retrieved on: 
Tuesday, March 12, 2024
Human, Conference, ATTD, CKD, Patient, Diabetes, EGFR, Safety, Chronic kidney disease, DKA, Hypoglycemia, Pharmaceutical industry

In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.

Key Points: 
  • In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.
  • The efficacy and safety data were presented last week at ATTD 2024 - 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy.
  • Relative to placebo, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts.
  • “We are optimistic that sotagliflozin may become an important new treatment option for this important population.”

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Retrieved on: 
Friday, March 8, 2024
Research, General Health, Technology, Medical Devices, Other Manufacturing, Health Technology, Clinical Trials, Science, Biotechnology, Wearables, Mobile Technology, Health, Diabetes, Manufacturing, TIR, Dexcom, CGM, Doctor of Philosophy, Randomized controlled trial, MD, Treatment, Medical director, G6, AID, Intervention, Conference, ATTD, Safety, Hypoglycemia, Control, RCT, T1D, Corporation, DKA, Body mass index, Treatment and control groups, Pharmaceutical industry

The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.

Key Points: 
  • The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
  • "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
  • The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
  • In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.

JDRF Applauds Usher and NFL Star Noah Gray for Shining a Spotlight on Type 1 Diabetes at Super Bowl LVIII

Retrieved on: 
Monday, February 12, 2024
JDRF, Diabetes, Kansas City Chiefs, Super Bowl LVIII, Autoimmune disease, Research, Usher, Dream, Blood, Diabetic ketoacidosis, Super Bowl, Hospital, Sport, Risk, Autoantibody, Bowl game, Duke University, Pancreas, Insulin, Knowledge, Disease, T1D, Child, Diagnosis, SAN, NFL, DKA, Immune system, Pharmaceutical industry

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is recognizing Grammy award-winning megastar Usher and NFL Super Bowl Champion Noah Gray of the Kansas City Chiefs for shining a spotlight on T1D during Super Bowl LVIII.

Key Points: 
  • NEW YORK, Feb. 12, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is recognizing Grammy award-winning megastar Usher and NFL Super Bowl Champion Noah Gray of the Kansas City Chiefs for shining a spotlight on T1D during Super Bowl LVIII.
  • As Usher prepared for his highly anticipated Super Bowl Halftime Show and the release of his forthcoming album, he also prioritized raising awareness for T1D and the importance of screening.
  • "Usher's advocacy has played a crucial role in raising awareness about type 1 diabetes and the importance of early detection through screening," said Aaron Kowalski, CEO of JDRF.
  • Noah Gray, a standout tight end for the NFL Kansas City Chiefs, was diagnosed with T1D during his freshman year at Duke University.

Survey: 2/3 of Parents Unaware that Type 1 Diabetes is Identifiable Before Symptoms

Retrieved on: 
Thursday, December 7, 2023
Insulin, Incidence, Risk, Disease, Diabetic ketoacidosis, Autoimmune disease, Parent, Diagnosis, Diabetes, DLC, DKA, Medical device, Residential care, Nursing, T1D

WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- A new national survey commissioned by the Diabetes Leadership Council (DLC) found that nearly 2/3 (62%) of parents are unaware that type 1 diabetes (T1D) can be identified before symptoms occur. The findings come at a time when T1D is typically diagnosed in the final of three stages when a person begins experiencing symptoms, blood sugar is high, and insulin dependence begins.

Key Points: 
  • WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- A new national survey commissioned by the Diabetes Leadership Council (DLC) found that nearly 2/3 (62%) of parents are unaware that type 1 diabetes (T1D) can be identified before symptoms occur.
  • In DLC's online survey of 1,000 parents of children aged 17 and younger, findings indicate that parents may misunderstand T1D risk and are unaware of screening options to identify risk early.
  • Only one-third (38%) of parents surveyed are aware that risk for T1D can be identified before experiencing symptoms.
  • Parents should talk with their family doctor about screening options to learn which option may be right for them.

Nick Jonas and Beyond Type 1 Launch #SeeTheSigns, a National Campaign to Help People Recognize the Symptoms of Diabetes and Receive a Diagnosis

Retrieved on: 
Monday, November 13, 2023
Choking, National Diabetes Education Program, Kidney disease, Risk, Amputation, Diabetic ketoacidosis, Stroke, Urination, Social media, Health, Thirst, Diabetes, Diagnosis, Death, Health education, Prediabetes, Life, Diabetic coma, Weight loss, DKA, Pharmaceutical industry

SAN MATEO, Calif., Nov. 13, 2023 /PRNewswire/ -- For the 8.5 million American adults living with undiagnosed diabetes, recognizing the symptoms can determine the difference between life and death—and greatly reduce the likelihood of long-term complications due to a missed or delayed diagnosis.

Key Points: 
  • To address this epidemic crisis, Beyond Type 1 today announced #SeeTheSigns, a national campaign to help people effectively identify the symptoms of diabetes in themselves and others.
  • Unlike the signs of a stroke, choking and other life-threatening emergencies, the symptoms of diabetes often go unnoticed and unaddressed for some time.
  • "I was lucky to receive my diagnosis at age 13 when my mom noticed the signs —but many aren't as lucky.
  • While type 2 diabetes is more common, it's only diagnosed in about half of those whose bodies show symptoms.

Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis

Retrieved on: 
Wednesday, October 18, 2023
Cardiac arrest, Volatile organic compound, Kidney, Diabetes, DKA, Qi, Ketone, Cell, Type 1 diabetes, Acetone, VOC, Type 2 diabetes, Diabetic ketoacidosis, Patient, Death, Coma, Insulin, Pharmaceutical industry, Medical device

DKA is a serious complication of diabetes that can be life-threatening. DKA is most common among children with Type 1 diabetes, however adults with Type 2 diabetes can also develop DKA. DKA occurs when the insulin level drops rapidly and can’t drive blood sugar into the cells for use as fuel supply. Under this condition, the liver starts to break down fat for energy -- a process that generates acidic substances called ketones, which can accumulate to dangerous levels in the body. Acetone is a volatile ketone which can be detected in the breath. If left untreated, DKA can escalate within 24 hours into life-threatening conditions such as brain swelling, cardiac arrest, kidney damage, coma and death.

Key Points: 
  • FREEHOLD, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it has partnered with Qi Diagnostics Limited (“Qi Diagnostics”) to co-develop international multi-center clinical studies for DKAir™ breathalyzer device for the early detection of diabetic ketoacidosis (“DKA”).
  • Qi Diagnostics has developed DKAir™ a handheld breathalyzer that allows diabetic patients to blow into the breathalyzer to detect the acetone levels in their breath.
  • We are excited to partner with Qi Diagnostics to co-develop international multi-center clinical studies for DKAir™.
  • The preclinical research has been completed and we expect the clinical studies to start in the first quarter of 2024.”

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, Fatal, Weakness, Female, Skin, PD-L1, Creatinine, DKA, Nausea, Swelling, Keratitis, Pneumonia, Birth, PD-1, Hair, Neutrophil, Male, Peripheral neuropathy, Lipase, Acute kidney injury, Blood, Stevens–Johnson syndrome, Toxic epidermal necrolysis, Diabetic neuropathy, Toxicity, Bulla, Temperature, Appetite, Itch, SJS, Fetus, Cornea, Conjunctivitis, Hyperglycemia, Dermatitis, Evaluation, Hypoxia, Pain, Diabetic ketoacidosis, Pembrolizumab, ILD, Risk, Liver, Lymphocyte, Grade 2, Rash, Erythema, Fatigue, Acral lentiginous melanoma, Pneumonitis, Papule, Incidence, Dysgeusia, Anemia, Cough, Urinary tract infection, Diarrhea, Erythroderma, Periodic breathing, TEN, Patient, MUC, PN, Drug eruption, Septic shock, Pharmaceutical industry, Medical imaging, Palladium

Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.

Key Points: 
  • Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.
  • When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate.
  • Skin reactions occurred in 72% (all grades) of the 121 patients treated with PADCEV in combination with pembrolizumab in clinical trials.
  • The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash.

Holu Hou Energy Signs Contract for Solar + Storage at Newly Constructed Daniel K. Akaka State Veterans Home in Hawaii; Onyx Renewables to Finance and Operate Portfolio

Retrieved on: 
Tuesday, June 27, 2023
State, Edward C. Allworth Veterans' Home, Nursing, Bed, Multifamily residential, Residential area, Electricity, Veteran, DKA, New York State Veterans' Home at Oxford, Old, Dementia, PPA, BESS, Renewable energy, Onyx

The system will provide lower cost electricity to the facility as well as grid resiliency via the Scheduled Dispatch Program.

Key Points: 
  • The system will provide lower cost electricity to the facility as well as grid resiliency via the Scheduled Dispatch Program.
  • The renewable energy system will be constructed in 2023 and will include 518.8 kW of photovoltaics (PV) and 1,305 kWh of battery energy storage (BESS).
  • As owner and operator of the assets, Onyx will fully fund and maintain the solar plus storage systems, thereby requiring no initial investment or upfront cost to the new State Veterans Home.
  • “Onyx Renewables is pleased to be partnering with Holu Hou Energy to provide onsite solar and storage solutions to the DKA Veterans Home facility on Oahu,” stated Mary Beth Mandanas, CEO of Onyx.

JDRF Joins Diabetes Professionals at the American Diabetes Association 83rd Scientific Sessions to Celebrate Advancements in Type 1 Diabetes Research

Retrieved on: 
Monday, June 26, 2023
Injection, JDRF, San Diego Convention Center, Insulin, Sessions, Diabetes, T1D, Vertex, Clinical trial, Research, DKA, Melton, American Diabetes Association, Vertex Pharmaceuticals, ADA, SGLT, Disease, Pharmaceutical industry

JDRF-supported research has been highlighted at the annual event since JDRF started funding research nearly 50 years ago.

Key Points: 
  • JDRF-supported research has been highlighted at the annual event since JDRF started funding research nearly 50 years ago.
  • "JDRF looks forward to the ADA Scientific Sessions each year for the opportunity to come together as a community, learn from one another, and showcase the innovation and progress across the spectrum of diabetes research.
  • For decades, JDRF's leadership in driving type 1 diabetes research has been featured at the Sessions," said Aaron Kowalski, Ph.D., JDRF CEO.
  • "The research presented at the ADA Scientific Sessions demonstrates the incredible momentum that is accelerating breakthroughs to find cures, prevent the disease, and treat type 1 diabetes and its complications.

Duo Health Partners with Desert Kidney Associates for First-of-its-Kind Value-Based Care Model in Arizona

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Men, Diabetes, Health, Consumer, Other Health, Practice Management, Telemedicine, Virtual Medicine, General Health, Hospitals, Health Insurance, Women, Seniors, Nursing, Quality of life, CKD, Patient, Nephrology, Chronic kidney disease, Disease, Partnership, Kidney disease, Health, Risk, PLC, ESKD, DKA, Ethics, Multimedia, Health equity, Prevalence, Physician, Associate, Medicine

Duo Health announced today a first-of-its-kind partnership in Arizona with Desert Kidney Associates (DKA), a nephrology practice with longstanding community ties.

Key Points: 
  • Duo Health announced today a first-of-its-kind partnership in Arizona with Desert Kidney Associates (DKA), a nephrology practice with longstanding community ties.
  • Duo Health is a new type of value-based medical group purpose-built to manage chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in collaborative relationships with nephrology and multi-specialty practices.
  • View the full release here: https://www.businesswire.com/news/home/20221220005215/en/
    Desert Kidney Associates and Duo Health Announce Partnership in Arizona.
  • The Duo Health team is comprised of leaders in value-based health care, technology and behavioral science who share a vision for advancing health equity one relationship at a time.